BACKGROUND: The impact of CX3CR1 polymorphisms on human immunodeficiency virus type 1 (HIV-1) pathogenesis is controversial, with conflicting reports of their role in disease progression in HIV-1-infected adults. METHODS: A cohort of 1055 HIV-1-infected children were genotyped for 2 CX3CR1 polymorphisms, V/I249 and T/M280, and their impact on HIV-1-related disease progression, including central nervous system (CNS) impairment, was evaluated. RESULTS: Children with the CX3CR1 I/I249 genotype experienced more-rapid disease progression (I/I249 vs. V/V249: relative hazard [RH], 2.19 [95% confidence interval {CI}, 1.30-3.68], P=.003; I/I249 vs. V/I249: RH, 1.77 [95% CI, 1.00-3.14], P=.05) and a trend toward more CNS impairment (I/I249 vs. V/V249: RH, 2.19 [95% CI, 1.00-4.78], P=.049; I/I249 vs. V/I249: RH, 2.02 [95% CI, 0.85-4.83], P=.11). Children with the V249-T280 haplotype experienced significantly less disease progression (RH, 0.42 [95% CI, 0.24-0.73]; P=.002) and CNS impairment (RH, 0.39 [95% CI, 0.39-0.22]; P=.001). Of note, these effects remained significant after CD4+ lymphocyte count and plasma HIV-1 RNA load at baseline were adjusted for and in a longitudinal, multivariate analysis. CONCLUSIONS: CX3CR1 genotypes and haplotypes impact HIV-1 disease progression independently of CD4+ lymphocyte count and plasma HIV-1 RNA load, suggesting that the fundamental role of CX3CR1 in the alteration of disease progression might be the recruitment of immunomodulatory cells responsible for the control of HIV-1.
BACKGROUND: The impact of CX3CR1 polymorphisms on human immunodeficiency virus type 1 (HIV-1) pathogenesis is controversial, with conflicting reports of their role in disease progression in HIV-1-infected adults. METHODS: A cohort of 1055 HIV-1-infectedchildren were genotyped for 2 CX3CR1 polymorphisms, V/I249 and T/M280, and their impact on HIV-1-related disease progression, including central nervous system (CNS) impairment, was evaluated. RESULTS:Children with the CX3CR1 I/I249 genotype experienced more-rapid disease progression (I/I249 vs. V/V249: relative hazard [RH], 2.19 [95% confidence interval {CI}, 1.30-3.68], P=.003; I/I249 vs. V/I249: RH, 1.77 [95% CI, 1.00-3.14], P=.05) and a trend toward more CNS impairment (I/I249 vs. V/V249: RH, 2.19 [95% CI, 1.00-4.78], P=.049; I/I249 vs. V/I249: RH, 2.02 [95% CI, 0.85-4.83], P=.11). Children with the V249-T280 haplotype experienced significantly less disease progression (RH, 0.42 [95% CI, 0.24-0.73]; P=.002) and CNS impairment (RH, 0.39 [95% CI, 0.39-0.22]; P=.001). Of note, these effects remained significant after CD4+ lymphocyte count and plasma HIV-1 RNA load at baseline were adjusted for and in a longitudinal, multivariate analysis. CONCLUSIONS:CX3CR1 genotypes and haplotypes impact HIV-1 disease progression independently of CD4+ lymphocyte count and plasma HIV-1 RNA load, suggesting that the fundamental role of CX3CR1 in the alteration of disease progression might be the recruitment of immunomodulatory cells responsible for the control of HIV-1.
Authors: Stephen A Spector; Kumud K Singh; Saurabh Gupta; Lucette A Cystique; Hua Jin; Scott Letendre; Rachel Schrier; Zunyou Wu; Kun X Hong; Xin Yu; Chuan Shi; Robert K Heaton Journal: AIDS Date: 2010-06-19 Impact factor: 4.177
Authors: Amie L Meditz; Rick Schlichtemeier; Joy M Folkvord; Monique Givens; Kevin C Lesh; M G Ray; Martin D McCarter; Elizabeth Connick Journal: AIDS Res Hum Retroviruses Date: 2008-07 Impact factor: 2.205
Authors: Kumud K Singh; Michael D Hughes; Jie Chen; Kelesitse Phiri; Christine Rousseau; Louise Kuhn; Anna Coutsoudis; J Brooks Jackson; Laura A Guay; Philippa Musoke; Francis Mmiro; Richard D Semba; Stephen A Spector Journal: J Acquir Immune Defic Syndr Date: 2008-11-01 Impact factor: 3.731
Authors: M Jurado; J Sainz; C B Lupiañez; M Martínez-Bueno; J M Sánchez-Maldonado; J Badiola; C Cunha; J Springer; M Lackner; J Segura-Catena; L M Canet; L Alcazar-Fuoli; M A López-Nevot; L Fianchi; J M Aguado; L Pagano; E López-Fernández; M Alarcón-Riquelme; L Potenza; S M Gonçalves; M Luppi; L Moratalla; C Solano; A Sampedro; P González-Sierra; M Cuenca-Estrella; K Lagrou; J A Maertens; C Lass-Flörl; H Einsele; L Vazquez; J Loeffler; R Ríos-Tamayo; A Carvalho Journal: Infect Immun Date: 2020-03-23 Impact factor: 3.441